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The Structural Proteomics In Europe (SPINE) programme is
aimed at the development and implementation of high-
throughput technologies for the efficient structure determina-
tion of proteins of biomedical importance, such as those of
bacterial and viral pathogens linked to human health. Despite
the challenging nature of some of these targets, 175 novel
pathogen protein structures (220 including complexes) have
been determined to date. Here the impact of several
technologies on the structural determination of proteins from
human pathogens is illustrated with selected examples,
including the parallel expression of multiple constructs, the
use of standardized refolding protocols and optimized crystal-
lization screens.
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1. Introduction and target selection
The aim of the Structural Proteomics In Europe (SPINE)
programme was to develop and exploit technological advances
in structural biology to tackle difficult problems related to
human health and disease. To this end, SPINE workpackage 9
focused on proteins from human pathogens, especially
bacterial and viral, whereas work on human targets was
addressed by workpackages 10 and 11 (see Banci et al., 2006).
This article reports on the progress made in the study of
pathogen targets and provides highlights of a number of
developments in high-throughput (HTP) technologies which
have proved crucial to successful structure determination,
illustrated by reference to some of the structures solved.
Whilst relevance to human health and disease was the over-
arching criterion for target selection, a subset of targets was
selected explicitly as so-called ‘low-hanging fruit’. These,
primarily exemplified by the Bacillus anthracis proteins (Au et
al., 2006), proved particularly valuable in validating HTP
pipelines and technologies. The methods used by the various
SPINE partners for target selection and other informatics
aspects are described in detail in Albeck et al. (2006).
1.1. Bacterial targets
The bacterial organisms targeted for structural analysis
represent a range of threats to human health, including food
poisoning, respiratory diseases and potential bio-terrorism
agents, of which all manifest antibiotic resistant strains. The
two key organisms were Mycobacterium tuberculosis (MTB)
and B. anthracis, which together accounted for 81% of our
bacterial targets and 47% of the bacterial protein three-
dimensional structures solved (Table 1). The efforts on MTB
involved six partners (Paris, Hamburg, Uppsala, Stockholm,
York and the Weizmann) and especially targeted proteins
from strain H37Rv. The B. anthracis project was a collabora-
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Table 1
Bacterial and viral structures solved.
Bacterial targets are shown in normal type, viruses in bold and other
organisms in italic. Pathogen species are MT, M. tuberculosis; MS,
M. smegmatis; BA, B. anthracis; BS, B. subtilis; NM, N. meningitides; NG,
N. gonorrhoeae; CJ, C. jejuni; EC, E. coli; SP, Streptomyces purpurascens; SG,
S. galileus; SN, S. nogalater; SC, S. calvalugarus; OT, other bacteria; VV,
vaccinia virus; EBV, Epstein–Barr virus; SARS, severe acute respiratory
syndrome; MHV, murine hepatitis virus; MVE, Murray Valley encephelitis
virus; TEV, tobacco etch virus; BTV, bluetongue virus; BV, Banna virus; ERV,
equine rhinitis virus; MV, measles virus.
Species Protein name PDB code
MT Protein phosphatase
MT Hypothetical trans factor 2g9w
MT AhpE
MT Hypothetical protein
MT Uridylate kinase
MT Cyp121 1n4g
MT Hypothetical protein 1rfe
MT Thymidylate kinase 1n5j
MT DapB 1yl6/1yl5/1yl7
MT LeuB 1w0d
MT Lipoate protein ligase B 1w66
MT Putative antiterminator 1s8n
MT CmtR 2g8p
MT Pyrophosphatase 1sxv
MT Sulfite reductase NirA 1zj8/1zj9
MT Rv1155 1w9a
MT Rv2945c, lipoprotein 2byo
MT Hypothetical protein 2fwv
MT Protein kinase B 1o6y/2fum
MT Hypothetical protein 2ckd
MT Hypothetical protein 2bi0
MT ClpP 2cby/2ce3
MT Adenylate kinase 2cdn/1p4s
MT AhpC 2bmx
MT Rv2740, hydrolase 2bng
MT PpiA 1w74
MT Ribose 5-p isomerase B 1usl
MT Rv1284, carbonic anhydrase 1ylk
MT Rv3588, carbonic anhydrase 1ym3
MT Hypothetical protein 2bi0
MT Hypothetical protein 2c2i
MS Phosphatidylinositol transferase 2gej/2gek
MS Protein phosphatase
BA Thymidylate kinase BA0027
BA Hypothetical protein BA0541
BA Phosphoglycerate kinase BA5367
BA Spo0E phosphatase BA5174
BA Cyclo-ligase BA0296 2btu
BA Thiolase BA5489 2c5s
BA UDP-epimerase BA5505 2c2o
BA Monooxygenase BA2919
BA Gly transferase BA1558
BA BA0291-s-carboximide
BA Ligase BA1563
BA Alanine dehydrogenase BA0592
BA Cytidine deaminase BA4525
BA Nucleoside hydrolase BA2400 2c40
BA G3PDH 2 BA5369
BA G3PDH 1 BA4827
BA P-kinase BA3382
BA P-kinase BA4843
BA Cycloligase BA4489
BA Translation factor P BA4421
BA Uridylate kinase BA1797
BA Naphthoate synthase BA5109
BA Docking protein ftsy BA3985
BA Hydratase/isomerase BA3583
BA Alanine racemase BA0252
BA LOLS protein BA4318
BA Thi1 BA4899
BA Met-aminopeptidase BA0132
Table 1 (continued)
Species Protein name PDB code
BA 3-Oxo-acyl reductase BA3989
BA Ribulose-p-epimerase BA3998
BA Histidyl-tRNA synthetase BA4633
BA Enolase BA5364
BA Arginase BA0154
BA Hydratase/isomerise BA2356
BA YisI, BA1655 2bzb
BA Dihydrodipicolinate synthase BA3935 1xky/1xly
BA PN phosphorylase BA1483 1xe3
BA pure BA0288 1xmp
BA GuaC BA5705 1ypf
BA Ferrochelatase BA1071 2c8j
BA Endonuclease IV BA4508 1xp3
BA Superoxide dismutase BA4499 1xre
BA Superoxide dismutase BA5696 1xuq
BS Forespore regulator Bsu2771 2bw2
BS dUTPase YncF Bsu1767
BS Transcription regulator 2b182bo1
BS CsrA 1t30
BS dUTPase YosS Bsu2001
BS PhoP 1mvo
BS P104H BsSOD 1xtl
BS Y88H-P104H BsSOD 1xtm
BS AppA 1xoc
BS Sco1 1on4
BS S46V CopAa 1oq3
BS S46VCopAab 1p6t
BS SOD-like protein 1rp6
BS SOD-like protein 1s4i
NM LysR transcription factor
NM MarR transcription factor
NM Lrp transcription factor
NM Yjgf family regulator
NM Pii GlnB protein 2gw8
NM MarR
NM IIAntr protein 2aoj
NG Specific regulator
CJ SurE survival protein
CJ Periplasmic binding protein
CJ Solute-binding protein
CJ Cysteine-binding protein 1xt8
CJ dUTPase Cj1451 1w2y
EC Carboxypeptidase Dcm 1y79
EC ATP NAD kinase
EC Biosynthesis-like protein
EC tRNA pseudouridine syn 1szw
EC Diacylg-kinase catalytic 1bon
EC Type III CoA transferase 1xa3
EC Protein ribD
EC Hyp-protein yebU
EC UPF0010 protein
EC CutA1 1naq
SP Aclacinomycin m-esterase 1q0z
SP Aclacinomycin hydroxylase 1qzz
SP C-4-O-methyltransferase 1tw2/1tw3
SG Anthracycline 1-hydroxylase
SN NA methyl-ester-cyclase 1sjw
SN Snoal2 1-hydroxylase
SC BLIP_Mut1
SC BLIP_TEM_2 1xxm
SC BLIP_TEM_3 1s0w
OT P275D-TbADH
OT Tb_Eh_ADH
OT Cb_Tb_ADH
OT Tb_Cb_ADH
OT PaADH
OT D275P_EhADH
OT DiVK 1mb3
OT CopC 1ot4
OT 1,3-PD-dehydrogenase
OT Carbonate dehydratase
OT Periplasmic binding protein
tive effort between the Oxford and York partners and a fuller
assessment of this is given in an accompanying paper (Au et
al., 2006). In addition to these, smaller numbers of targets were
selected from Campylobacter jejuni (York, Lisbon), two
members of the Neisseriae family (N. meningitidis and N.
gonorrhoeae; Oxford), Escherichia coli (e.g. 0157:H7; Stock-
holm, Weizmann, Florence), Klebsiella pneumoniae (Lisbon)
and Streptomycetes (Stockholm) and Shigella flexnin, Salmo-
nella entrica typhimurium and Streptococcus pyogenes (Weiz-
mann).
1.1.1. M. tuberculosis. A number of slow-growing myco-
bacterial species have evolved into highly successful human
pathogens and are responsible for diseases such as tubercu-
losis (TB; M. tuberculosis and M. africanum) and leprosy
(M. leprae). The World Health Organization estimates that
one-third of the human population is currently infected and
that one person dies roughly every 18 s (http://www.who.int)
from mycobacterial diseases. There are now forms of
M. tuberculosis (MDR-TB; Espinal, 2003) resistant to the two
most powerful anti-TB drugs (isoniazid and rifampicin) and
there is a pressing need for new drugs effective against
persistent TB infection andMDR-TB. Closely related forms of
mycobacteria are pathogenic to other mammalian species, e.g.
M. bovis. The MTB target-selection process in Paris is illus-
trative of those used for this organism in SPINE and was based
on comparative analyses of the complete genome sequences
for two MTB strains with other bacteria and mycobacterial
strains, such as M. bovis, M. bovis BCG and M. leprae, which
provided detailed information about every gene in MTB. Over
300 proteins were identified that were only found in myco-
bacteria or actinomycetes, but were conserved in the degraded
genome of M. leprae and therefore presumed to be important
for bacterial viability and hence potential drug targets (Albeck
et al., 2006). In addition, the Paris laboratory targeted proteins
for which structures would provide insights into MTB biology.
Funding for the MTB project was far from exclusive to SPINE
and came from several other sources, including other EC
grants.
1.1.2. B. anthracis. York and Oxford each selected initial
sets of 48 targets from B. anthracis, with the dual aim of
determining a reasonable number of structures and, in the
process, helping to refine their protein-production pipelines
(Au et al., 2006). To be considered, the protein had, in general,
to be reasonably small (<50 kDa), lacking in regions predicted
to be transmembrane moieties, signal peptides or disordered
and usually amenable to structure solution by molecular
replacement. York targets included proteins involved in
nucleotide metabolism and sporulation, whilst Oxford targets
included members of protein families well conserved across a
range of pathogenic bacteria (Au et al., 2006). An additional
SPINE collaboration between York and Utrecht resulted in
two NMR structures of sporulation-associated aspartic acid
phosphate phosphatases, neither of which could be crystal-
lized (AB et al., 2006), and extended the targets to the BofC
(bypass of forespore C) protein from B. subtilis, an inter-
compartmental signalling factor expressed in the forespore
(Patterson et al., 2005), also found in B. anthracis (BA4653).
1.1.3. Neisseria. Many species of this Gram-negative
-proteobacteria are found only in humans. Two members of
the Neisseriae, N. meningitidis and N. gonorrhoeae, have
evolved into highly successful pathogens responsible for
bacterial meningitis and gonorrhoea, respectively. Although
the regulatory systems of all Gram-negative bacteria share
features in common with E. coli, Neisseria species display
several features which are unique. These include a restricted
set of sigma factors, a relatively small number of transcrip-
tional regulators and a large number of phase variable genes.
Oxford focused on the complete repertoire of transcription
regulators in both N. meningitidis and N. gonorrhoeae, with a
view to defining the structure–function relationships of these
proteins and to provide key reagents for experimental studies
of regulation. The four available complete genome sequences
(Parkhill et al., 2000; Tettelin et al., 2000) of Neisseria were
assessed for homologues of DNA-binding proteins with
potential regulatory functions. Representative orthologues of
each regulator in each genome were identified, with the genes
selected in order of preference from N. meningitidis strain
MC58, N. gonorrhoeae strain FA1090, N. meningitidis strain
research papers
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Table 1 (continued)
Species Protein name PDB code
OT Alcohol dehydrogenase 2b83
OT P-carrier protein hpr 1ka5
OT P-carrier protein hpr 1txe
OT Atx1-apo 1sb6
OT cadA ATPase 2aj0/2aj1
OT P275D-TbADH
OT CheY2 1p6q
OT tRNA synthetase homolog
OT CR1885 1x9l
OT DiVK 1mb3
OT ctag 1so9
VV B14R
VV N1L
VV CmrE
VV A41L
EBV U-DNA glycosylase
EBV BKRF3
EBV BLLF3 2bsy
EBV BVRF2 1o6e
EBV BARF1 2ch8
SARS Macro domain 2fav
SARS Orf 9 b 2cme
SARS Entire NSP9 1qz8
SARS Nsp9 1uw7
MHV Nsp9
MVE Methyltransferase
TEV NIa protease
PM2 Spike protein P1
Phi-6 P2 polymerase
Phi-13 P4 translocase
BTV VP4 guanylyltransferase
BTV Nonstructural ns2
BV VP9 capsid protien
ERV ERAV capsid
MV Domain of P 2bet
Bil170 Bil170 RBP
p2 P2 RBP/complex 2bsd/2bse
Tick TdPI
Tick TdPI/complex
Tick dS salivary peptide
Prot Carbonic anhydrase 1y7w
Z2491 and N. meningitidis strain FAM18, to provide a cohort
of 62 DNA-binding and associated signal-transduction
proteins. In the vast majority of cases, the entire protein was
targeted for analysis.
1.1.4. A pan-bacterial attack on copper-binding proteins.
To address the role of copper in cellular processes, the Flor-
ence laboratory targeted copper-binding proteins. Bacterial
and eukaryotic genomes were compared to identify prokary-
otic orthologues of proteins in yeast and humans. The aim was
to solve high-resolution NMR structures that could be used as
models for human proteins and to identify differences
exploitable for potential antibacterial drugs. Additionally,
target selection was limited to proteins of fewer than 200
residues, as they are more tractable for NMR (Banci &
Rosato, 2003). Structures were solved from a range of
bacterial species including B. subtilis, E. coli and Pseudo-
monas aeruginosa (AB et al., 2006).
1.2. Viruses
A number of different viruses were targeted, ranging from
large double-stranded DNA (dsDNA) viruses such as
Epstein–Barr virus (EBV; Grenoble) and vaccinia virus
(VACV; Oxford), to single-stranded RNA viruses such as the
newly emergent human pathogen, the severe acute respiratory
syndrome coronavirus (SARS-CoV; Marseille and Oxford).
Finally, some viruses of less direct relevance to human health
were investigated as model systems, for instance bacterio-
phage P2 (Marseille).
1.2.1. Poxviruses. This group of very large viruses includes
variola virus, the aetiological agent of smallpox, and vaccinia
virus (VACV), used as the smallpox vaccine. Their genomes
each contain 200 open reading frames (ORFs) and the
sequences of more than 20 poxviruses reveal considerable
sequence variability towards each end of the genome. These
regions code for genes that affect virus virulence, host-cell
susceptibility and the host response to infection (Gubser et al.,
2004), enabling the virus to suppress the immune response
(Smith et al., 1997, 1999). In VACV half of the genes are non-
essential for replication and a significant number are
immunomodulators; nine of which were targeted by Oxford as
being reasonably small but of significant potential biological
interest.
1.2.2. Herpesviruses. Members of this family of dsDNA
viruses have large genomes (100 ORFs) and are responsible
for a diverse set of human diseases. Examples include herpes
simplex virus (HSV; causing genital herpes and herpes
encephalitis), EBV (causing Burkitts lymphoma and glandular
fever), varicella zoster virus (VZV; causing chickenpox and
shingles), human herpesvirus-8 (HHV-8; implicated in all
forms of Karposi sarcomas, commonly seen in AIDS patients)
and human cytomegalovirus (CMV; causing AIDS-related
retinitis and pneumonia). No effective treatments are gener-
ally available, with the exception of the acyclovir compounds
active against HSV. Thus, herpesviruses are of immediate
interest to the biomedical community and in particular to the
pharmaceutical industry. Barcelona and Oxford have interests
in the molecular mechanisms of genome packaging and
targeted a number of proteins that form the complex that
packages the dsDNA genome of herpesviruses. This work
demonstrated the inadequacy of the current E. coli protein-
production pipelines for such difficult proteins (five out of six
of the components are greater than 70 kDa in size and all are
part of complex robust macromolecular assemblies), since all
the expressed proteins were insoluble. Soluble proteins have
now been produced in insect cells for some of these targets,
but no structures have been determined and this work will not
be considered further here. In contrast, the Grenoble group
targeted EBV proteins with known enzymatic activity and
ranked them based on a number of properties, prioritizing
those that were small and predicted to be stable with a high
secondary-structure content. Surface glycoproteins and those
proteins forming multi-component complexes were explicitly
excluded. Application of these selection criteria led to the
structure determination of four proteins from EBV
(Tarbouriech et al., 2006).
1.2.3. Coronaviruses. SARS emerged as a new human
disease in southern China in late 2002. The first manifestation
of infection is a febrile illness, with respiratory symptoms,
headaches and myalgia, followed by progression to acute
respiratory distress and progressive respiratory failure (Peiris
et al., 2003). The disease is caused by a coronavirus (Kuiken et
al., 2003), one of a group of enveloped positive-strand RNA
viruses commonly associated with enteric and respiratory
disease (Ziebuhr & Siddell, 2002). The unusual severity of
SARS-CoV infection probably reflects the introduction of an
animal coronavirus into a susceptible human population. In
the first outbreak at least 8000 people were infected and there
were more than 750 fatalities (Donnelly et al., 2003). The
SARS-CoV genome is composed of at least 14 functional
ORFs that encode three classes of proteins: structural (S, M, E
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Figure 1
SPINE bacterial and viral target scoreboards. A snapshot (September
2005) of the pipeline for both bacterial and viral targets, drawn as a bar
chart, with bacterial targets in purple and viral in blue. The vertical axis is
represented on a log scale.
and N), non-structural involved in viral RNA synthesis (nsp or
replicase) and proteins thought to be non-essential for repli-
cation in tissue culture but that clearly provide a selective
advantage in vivo (the nspX or accessory proteins; Marra et
al., 2003; Rota et al., 2003). A number of proteins, primarily
from the large replicase polyproteins ORF1a and ORF1ab of
SARS-CoV, have been targeted by Oxford and Marseille to
test the efficacy of a focused structural proteomics approach
against a newly emerging human pathogen. Proteins were
excluded on the basis of certain criteria, such as size,
glycosylation and the presence of transmembrane regions.
2. Scoreboard for bacterial and viral proteins
As with all large-scale projects, the ‘Scoreboard’ is only a
snapshot of target progress through the various pipeline stages
and is therefore not a definitive assessment. It does, however,
allow an assessment of whether there are particular bottle-
necks that need addressing. The numbers for this section are
from a comprehensive snapshot of the project taken in
September 2005 (overall summary presented in Fig. 1),
whereas the detailed numbers for individual projects are for
early 2006 (Table 1). A comparison of the number of
expression trials with the number of crystals or good HSQC
data sets for the entire SPINE project shows that around 10%
of constructs led to the production of a protein suitable for
structural analysis. This attrition arises from approximately
equal losses at the expression stage and crystallization or
sample preparation stages (for NMR).
Most of the proteins were expressed in prokaryotic systems;
however, there is evidence, at least for human and viral
proteins, that significant gains are possible by the use of
eukaryotic expression systems, thus a global analysis of results
from SPINE partners shows that the success rate for
mammalian cell expression is more than twice that for soluble
expression in E. coli (75% versus 30%), with insect-cell
expression giving an intermediate success rate (44%). Further
development and uptake of these methodologies (see
Aricescu, Assenberg et al., 2006; Aricescu, Lu et al., 2006) is
likely to have a major impact on the study of difficult viral
targets, as indicated by preliminary results for EBV proteins,
where insect-cell expression yielded soluble protein for 50%
of the proteins tested (Tarbouriech et al., 2006)
2.1. Bacterial targets
The production of soluble protein for NMR and crystal-
lization studies is an absolute requirement, yet it remained a
significant bottleneck for the SPINE bacterial targets.
Bacterial expression statistics from all contributing SPINE
partners are illustrated in Fig. 1. Over 1000 proteins were
targeted and on average two or three constructs were
produced for each target and each construct was subjected to
two expression trials, with 29% of constructs producing
soluble protein. A more detailed analysis reveals significant
variability, with 77% of the first cohort of B. anthracis
constructs expressed in soluble form, but only 33% for MTB
and 15% for other bacteria. As of September 2005, almost
35% of these soluble proteins had produced protein crystals or
data suitable for NMR; these had resulted in structure solu-
tions for slightly more than 10% of the original 1127 targets
(Fig. 1). However, target groups which were carefully selected
for amenability for expression and structure determination,
such as the B. anthracis cohort, fared better, with success rates
in crystallization approaching 60% (Au et al., 2006).
2.2. Viral targets
The SPINE viral scoreboard (Fig. 1) suggests that although
viral proteins have a lower success rate for producing soluble
proteins than B. anthracis proteins, they are comparable to
more difficult bacterial and human proteins (27% of
constructs resulted in soluble expression at a level sufficient
for production and purification). However, the attrition rate
from protein purification to structure determination is higher,
with only about 30 crystal structures having been determined
to date. It appears that this is in part a consequence of the
difficulty of growing high-quality crystals. Thus, 34% of
soluble proteins crystallized compared with an equivalent rate
of 58% for the York/Oxford B. anthracis targets; furthermore,
many crystals were not of diffraction quality. However, as for
the bacterial targets, patterns of soluble protein expression
vary between viral systems. For some groups of viruses, such as
the poxviruses, the success rate for production in E. coli was
reasonable, as discussed below.
3. Pipeline technologies and case studies of their
impact
The protein-production technologies developed and used by
SPINE partners are covered in detail by Alzari et al. (2006)
and Aricescu, Assenberg et al. (2006) and aspects of work on
specific pathogen proteins are presented by Au et al. (2006)
and Tarbouriech et al. (2006). Target genes were often
amplified, cloned and screened for expression in parallel (e.g.
48 or 96 at a time). Ligation-independent cloning strategies
were widely (but not exclusively) used and the use of N- and
C-terminal His6 tags was almost universal. The automation of
many procedures, including small-scale expression screening,
was achieved using liquid-handling robots, with multi-channel
pipettes providing an inexpensive option for less automated
pipelines (expression-screening strategies are compared by
Berrow et al., 2006). Biophysical characterization methodolo-
gies usually included dynamic light scattering (DLS) and mass
spectrometry (ESI–MS) (see Geerlof et al., 2006). Protein
crystallization on the nanolitre scale was used by many of the
partners (Berry et al., 2006). Here we illustrate the impact of a
number of particular SPINE-based technologies on the
structure determination of pathogen targets, namely (i)
multiple-construct design for a single target, (ii) optimization
of protein solubility, (iii) eukaryotic expression systems, (iv)
standardized refolding protocols, (v) surface engineering and
(vi) other biophysical characterization.
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3.1. Multiple-construct design
The use of multiple constructs to define the correct N- and
C-termini of a target domain has had a crucial impact on the
successful structural analysis of both pathogen and human
targets (Banci et al., 2006; Siebold et al., 2005). An example of
this in the context of viral proteins is the N-terminal domain of
a viral methyltransferase, NS5, of Murray Valley encephalitis
virus (MVE), which was studied in Oxford. The domain
boundary was already reasonably well defined from the crystal
structure of the related methyl-transferase domain from
dengue virus (Egloff et al., 2002) and 18 constructs, comprising
of nine pairs of N- and C-terminal His6-tagged sequences,
were designed that varied the C-terminal end of the protein
domain. On the basis of automated small-scale expression
screening, six constructs were selected for production. DLS
indicated that all protein samples were monodisperse and
ESI–MS confirmed the molecular weights for the samples. The
His tags were cleaved (using the rhinovirus 3C cleavage site
for N-terminal His tags or by carboxypeptidase A treatment to
cleave back to a Lys for C-terminal His tags) and these
samples entered nanolitre-scale crystallization trials using the
standard Oxford set of 672 screens (Walter et al., 2005). Since
none of these screens gave crystals, the proteins were
subjected to lysine methylation (as described below), resulting
in crystals and a structure for one construct.
3.2. Solubility and functional optimization
Efforts to improve the solubility of MTB proteins illustrate
how the SPINE partners have tackled the problem of in-
soluble expression. MTB proteins are notoriously insoluble or
provide poor yields when expressed heterologously in E. coli
systems (Bellinzoni & Riccardi, 2003; Alzari et al., 2006), a
possible consequence of the high GC content of MTB genes
(65–70%) and unique codon preferences (de Miranda et al.,
2000). To address such problems, Hamburg contributed to the
development of anMTB expression system based on the faster
growing close relative M. smegmatis (Daugelat et al., 2003).
Proteins were expressed under close to physiological condi-
tions in order to ensure the correct post-translational modifi-
cations such as glycosylation and methylation. The published
protocol, using an inducible acetamidase promoter, was
modified to be compatible with the EMBL pETM vector
system (Geerlof et al., unpublished work). Using this system,
the MTB LipB enzyme was expressed with a covalently bound
ligand, which resulted in an X-ray structure at 1.08 A˚ resolu-
tion (Ma et al., 2006). When expressed in E. coli, a mixture of
native and ligand-bound enzyme was produced which failed to
crystallize. M. smegmatis expression was also used by the
Weizmann for the MTB multidomain eukaryotic like fatty-
acid synthase I (FASI; Zimhony et al., 2004) after E. coli
expression had yielded a soluble but non-functional FASI. A
recombinant M. smegmatis strain was constructed by deleting
the native fas1 gene and replacing it with the MTB (H37Rv)
fas1 gene using a site-specific integrating cosmid carrying the
MTB fas1 gene and its 50 and 30 flanking regions. This
produced a faster growing non-pathogenic M. smegmatis
(mc2155) derivative expressing MTB FASI.
In Paris, two strategies were adopted to enhance protein
solubility. Firstly, parallel cloning of orthologous myco-
bacterial genes from different species (i.e. M. tuberculosis,
M. leprae,M. smegmatis andM. bovis) was used to identify the
most soluble candidate. Secondly, cell-free protein expression
(Roche RTS) allowed the rapid evaluation of single gene
constructs. In the latter strategy, N-terminal codons were
optimized to identify the best silent mutation(s) for maximum
expression (Betton et al., 2004). Such cell-free systems provide
a fast standardized method for screening potentially toxic
protein expression without the inherent risks of using live
cells. Finally, in Stockholm, the MTB NirA protein could only
be obtained in a soluble form in E. coli following cloning and
co-expression with the cysG gene from Salmonella typhi-
murium, a gene that codes for an enzyme catalysing three
steps in the biosynthesis of sirohaem, a cofactor of NirA.
3.3. Baculoviral expression
Baculovirus-driven expression in insect cells has been used
for a number of viral proteins that were resistant to soluble
expression in E. coli. Although screening for expression in
such systems is at an early stage of development, the tech-
nology offers a viable alternative to bacterial expression for
‘high-value’ targets, as mentioned above for the EBV work.
An example from Oxford is the work on the capping enzyme
of bluetongue virus VP4, which, owing to problems of toxicity
in bacteria, was expressed in insect cells. This protein was
problematic during both purification and crystallization,
requiring the presence of high salt concentrations throughout.
In addition, production of SeMet-derivatized protein proved
difficult, prompting development of improved protocols for
labelling in insect cells (Sutton et al., unpublished work;
Aricescu, Assenberg et al., 2006).
3.4. Standardized refolding
Refolding from E. coli inclusion bodies was applied in a
number of viral projects, with varying degrees of success. The
extracellular immunomodulators of VACV studied in Oxford
provide a good example. These targets may be grouped
according to how they act: (i) secreted proteins that bind to
host factors that regulate complement, interferon (IFN),
chemokines, cytokines and inflammation (Smith & Alcami,
2000), (ii) intracellular proteins that modulate signalling
pathways, apoptosis or the antiviral action of IFN (Alcami et
al., 1999; Tortorella et al., 2000) and (iii) others that are
present on the infected cell’s surface and modulate the inter-
action of the infected cell with host factors and other cells.
Nine secreted immunomodulators of VACV were targeted for
expression, of which four were successfully refolded from
inclusion bodies (for the protocol, see Alzari et al., 2006),
resulting in the structure determination of two targets, one of
which, A41L, is highlighted below.
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3.5. Surface engineering as a tool in structural genomics
As noted above, a major bottleneck, particularly for the
viral targets, was the growth of crystals that were sufficiently
well ordered for structure solution. The crystallization of
proteins is dependent on their surface properties and it is well
established that flexible side chains (such as lysine residues)
on the surface of proteins reduce the likelihood of successful
crystallization (see, for example, Rayment, 1997). A straight-
forward method for changing the surface properties (‘surface
engineering’) of proteins is the reductive methylation of lysine
residues and this has been shown in some cases to yield
samples that are more amenable for growth of high-quality
crystals (Kobayashi et al., 1999; Kurinov et al., 2000; Schubot &
Waugh, 2004). To test the effectiveness of this method, Oxford
developed a simple, cheap and robust protocol and carried out
a systematic study of eukaryotic, bacterial and viral targets.
Ten proteins which had previously proved refractory to
structural analysis were successfully methylated and entered
into crystallization trials (Walter et al., 2006, in the press). To
date, this has led to three novel structures contributed to
workpackage 9, one being the MVE methyltransferase
domain discussed above.
3.6. Other biophysical characterization
The greatly enhanced use of MS for routine protein char-
acterization was a significant outcome of SPINE and proved of
value in numerous ways; for example, ESI–MS aided a revised
functional assignment of a C. jejuni extracytoplasmic solute
receptor (Cj0982), putatively annotated as a glutamine-
binding protein from its amino-acid sequence. The ESI–MS
spectrum of purified Cj0982 identified a peak with a mass of
125 greater than the mass of the protein alone. Following
crystallization and X-ray structure solution, a bound
l-cysteine ligand (mass 125) was identified (Mu¨ller et al.,
2005). Standard procedures have been developed in Oxford to
use ESI–MS to determine levels of post-translational modifi-
cation such as glycosylation (Geerlof et al., 2006). NMR target
proteins were checked for correct folding using 1H–15N
heteronuclear single-quantum correlation (HSQC) spectro-
scopy and metal-binding properties checked by atomic
absorption, using extended X-ray
absorption fine structure (EXAFS)
spectroscopy, UV–Vis spectroscopy and
(where appropriate) electron para-
magnetic resonance (EPR) spectro-
scopy. In several laboratories
(Marseille, Oxford, Stockholm), Ther-
mofluor analysis is routinely used to
monitor the temperature-dependence
of protein unfolding (Geerlof et al.,
2006) to define compounds to guide the
optimization of crystallization condi-
tions by stabilizing the protein.
4. Selected highlights
Here, we present examples chosen to
reflect different aspects of the broad
target areas: NirA from MTB and the
dUTPase of EBV are potential drug
targets, while work on Neisseria and
copper-binding proteins attempts to use
structure to further illuminate function
and the work on C. jejuni, SARS-CoV
and VACV shows how structure can
shed light on the possible roles for
proteins of unknown function. Finally,
the work on bacteriophage P2 shows
how a test case, used to evaluate HTP
procedures, can provide biologically
important data.
4.1. M. tuberculosis
Overall, 31 MTB structures have
been solved to date within SPINE and
here we provide a single example. One
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Figure 2
Structures of representative bacterial targets described in x4. All cartoons are drawn blue to red
from the N- to the C-terminus. (a) Schematic view of the structure of sulfite reductase, NirA, from
M. tuberculosis. The [Fe4–S4] cluster and siroheme cofactor are shown in ball-and-stick
representation (Schnell et al., 2005). (b) Schematic view of the structure of Neisseria IIAntr
(NMB 0736) with the phosphoryl acceptor histidine residue (His67) indicated (Ren et al., 2005). (c)
Schematic view of the structure of C. jejuni Cj0982 with bound cysteine ligand shown in ball-and-
stick representation (Mu¨ller et al., 2005). (d) Schematic view of the NMR structure of B. subtilis
CopA N-terminal domains (Banci et al., 2003a,b).
of the MTB genes upregulated in its persistent state is the
essential gene NirA (Rv2391), suggesting that it is a potential
target for the development of anti-tuberculosis agents. The
product of this gene, NirA protein, has been targeted by the
Stockholm group. The amino-acid sequence of NirA is
homologous to ferredoxin-dependent sulfite reductases and
the purified recombinant enzyme demonstrates a character-
istic [Fe4–S4] absorption spectrum. The structure of the
enzyme was determined using X-ray crystallography (Fig. 2;
Schnell et al., 2005). For this and other difficult projects
(including many MTB proteins), it was necessary to employ a
hand-crafted approach, exemplified by the requirement to use
streak-seeding to improve crystals and by the requirement for
co-expression noted above (x3.2). At the active site, the side
chains of Tyr69 and Cys161, located in close proximity to the
sirohaem cofactor, form an unusual covalent bond. Muta-
genesis of these residues decreased the catalytic activity of the
enzyme, with Y69A and C161S having the most deleterious
effect, suggesting that the covalent bond
is important but not essential for
enzyme activity. These residues are part
of a sequence fingerprint which distin-
guishes ferredoxin-dependent sulfite
from nitrite reductases. This is the first
three-dimensional structure obtained of
a ferredoxin-dependent sulfite/nitrite
reductase.
4.2. Neisseria
Genes for the cohort of 62 DNA-
binding and associated signal-transduc-
tion protein were amplified, cloned and
screened for expression in parallel and
the proteins were expressed, purified
and crystallized in parallel using the
standard OPPF pipeline. So far, the
structures of seven have been solved,
including the first bacterial leucine
response regulator (Lrp) protein
(NMB1650), a global regulator of
amino-acid metabolism (Calvo &
Matthews, 1994) and a MarR family
regulator (NMB1585). In E. coli, Lrp is
a global regulator of amino-acid meta-
bolism (Calvo & Matthews, 1994),
whereas MarR is a specific regulator of
the multiple antibiotic resistance
operon (Alekshun & Levy, 1997).
Studies are in progress to relate the
structures of the Neisseria transcription
factors to their function in this organism
and Thermofluor analysis has been used
to identify the amino-acid cofactor of
Lrp (Nichols et al., manuscript in
preparation). Amongst the signal
transduction proteins, it has been shown
that the structure of the N. meningitidis nitrogen regulatory
protein IIAntr (NMB0736; Fig. 2) confirms its assignment as a
functional homologue of the IIAntr proteins found in a range
of other Gram-negative bacteria (Ren et al., 2005).
4.3. C. jejuni
The Gram-negative pathogen C. jejuni is the leading cause
of gastroenteritis in humans and is responsible for 30% of
Guillain–Barre´ syndrome cases, a debilitating polio-like
autoimmune disease. C. jejuni colonizes the intestinal tract of
many animals (Svedhem & Kaijser, 1981) and is commensal in
poultry, cattle and swine (Harris et al., 1986; Kazwala et al.,
1990). The most promising route to reducing infections is to
reduce the incidence in poultry via vaccination. The C. jejuni
genome (Parkhill et al., 2000) harbours several genes encoding
highly antigenic proteins, three of which are the periplasmic
binding component of an ABC amino-acid transport system
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Figure 3
Structures of representative viral targets described in x4. All cartoons are drawn with each
monomer coloured from blue to red from the N- to the C-terminus. (a) The trimeric receptor-
binding protein from lactococcal bacteriophage P2. The threefold axis is vertical and the separate
architectural units of the molecule are labelled according to Spinelli et al. (2006). (b) The dimeric
molecule of SAR-CoV nsp9, viewed orthogonal to the molecular twofold axis. (c) Ribbon diagram
of A41L of VACV (M. Bahar, unpublished work). (d) Ribbon representation of EBV dUTPase in
complex with an atomic representation of dUMP (C, O, N and P atoms drawn in yellow, red, blue
and orange, respectively).
and include Cj0982, a major surface antigen and vaccine
candidate (Wyszynska et al., 2004). Such amino-acid uptake
systems are crucial to C. jejuni since it relies on amino acids as
a carbon source (its incomplete glycolytic pathway renders it
unable to use sugars; Kelly, 2001). York determined the crystal
structure of Cj0982, revealing that the ligand-binding pocket
contained a cysteine (Fig. 2), which was confirmed by ESI–MS
and tyrosine-fluorescence spectroscopy, suggesting that the
protein belongs to a cysteine-binding ABC-transport system
(Mu¨ller et al., 2005). This is the first structure of a cysteine-
transport protein. Crystallization experiments were initially
carried out at the Oxford Protein Production Facility and were
refined using an in-house Mosquito nanolitre-dispensing
robot. Five C. jejuni structures have been solved as part of the
SPINE project.
4.4. Copper-binding proteins
The Florence group have solved 20 novel structures of
copper-binding proteins by NMR. The copper homeostasis
systems they have characterized by NMR include the P-type
ATPase CopA from B. subtilis (Banci et al., 2002), a non-
pathogenic close relative of B. anthracis that also contains a
close CopA orthologue (BA3859). An unusual feature of
these P-type ATPases is that the cytoplasmic N-terminus has
one or more domains, depending on the complexity of the
organism, each containing a metal-binding motif. B. subtilis
CopA has two domains (CopAa and CopAb) with similar
amino-acid sequences, whereas the copper ATPases of other
bacteria have only one domain. NMR analysis revealed one B.
subtilis domain (CopAa) to be largely unstructured,
suggesting that it may be unfolded in vivo and not functional
(Banci et al., 2002). Sequence comparison of the two domains
and orthologous proteins suggested that Ser46 of CopAa may
destabilize the hydrophobic core of the domain, as hydro-
phobic residues (Val and Ala) occur frequently at this posi-
tion. Indeed, the single mutation S46V of CopAa produced a
completely folded domain. The structure of the CopA N-
terminal domain was solved by NMR (Fig. 2) and the inter-
action with its copper chaperone partner CopZ (from the
same operon) was also characterized (Banci et al., 2003a,b). It
is hypothesized that in vivo the folded functional domain is
favoured over an unfolded state, in a manner analogous to the
way that the N-terminus of the Wilson’s disease protein
interacts with its ATP-binding domain (Banci et al., 2003a).
4.5. Receptor-binding protein of bacteriophage P2
Marseille have investigated, as a test case, the mechanism of
cell entry by bacteriophage P2. This tailed phage infects
Lactococcus lactis, a Gram-positive bacterium used exten-
sively for the manufacture of fermented milk products.
Infection of L. lactis by tailed phages leads to serious financial
losses. Bacteriophage P2 infects specific L. lactis strains by
using a receptor-binding protein (RBP) located at the tip of its
non-contractile tail. As with the NirA protein, described
above, crystals suitable for X-ray diffraction experiments
could only be obtained by seeding. Bacteriophage P2 RBP is a
homotrimeric protein, each subunit of which comprises three
domains (Fig. 3): the shoulders (a -sandwich attached to the
phage), the neck (an interlaced -prism) and the receptor-
recognition head (a seven-stranded -barrel; Spinelli et al.,
2006). The complex of RBP with a neutralizing llama VHH5
domain allowed identification of the area on RBP that atta-
ches to the bacterial receptor (Spinelli et al., 2006), where it is
able to bind various saccharides (Tremblay et al., 2006). The
structural similarity between the recognition-head domain of
bacteriophage P2 and those of adenoviruses or reoviruses,
which invade mammalian cells, suggests that these viruses,
despite being evolutionarily distant and having different
chemical genomic composition (DNA versus RNA), may have
a common ancestral gene.
4.6. SARS-CoV nsp9
The SARS-CoV replicase gene encodes multiple enzymatic
functions (Snijder et al., 2003). These include an RNA-
dependent RNA polymerase activity (RdRp, nsp12), a 3C-like
serine proteinase activity (3CLpro, nsp5, also known as the
main proteinase, Mpro), a papain-like proteinase activity
(PL2pro, nsp3) and a superfamily 1-like helicase activity
(HEL1, nsp13). These types of proteins are common to the
replicative machinery of many positive-strand RNAviruses. In
addition, the replicase gene encodes proteins that have
domains likely to possess enzymatic activities associated with
RNA modification. Marseille and Oxford have studied SARS
proteins and have to date solved four separate structures using
the standard protein-production and crystallization pipelines
described by Alzari et al. (2006) and Berry et al. (2006). One of
these, the replicase protein nsp9, was solved by both partners
(Egloff et al., 2004; Sutton et al., 2004) and we discuss this
structure below.
Nsp9, encoded by ORF1a, has no designated function but is
most likely involved in viral RNA synthesis. The protein
comprises a single -barrel with a fold previously unseen in
single-domain proteins (Fig. 3). The topology superficially
resembles an OB-fold with a C-terminal extension and is
related to both of the two subdomains of the SARS-CoV 3C-
like protease (which belongs to the serine protease super-
family). Nsp9 has presumably evolved from a protease. The
crystal structure suggests that the protein is dimeric and this
was confirmed by analytical ultracentrifugation and light
scattering. Nsp9 binds RNA and appears to interact with nsp8.
The SPINE structural and functional analyses indicate that
nsp9 may play multiple roles in the replicative cycle of coro-
naviruses. Its interaction with other proteins may be essential
for the formation of the viral replication complex together
with its ability to interact with RNA (in the absence of other
proteins). The loops presented by the -barrel may principally
confer the RNA-binding capacity via non-specific interactions,
while the C-terminal -hairpin and helix, which display a
greater conservation across coronaviruses, are likely to be
involved in dimerization and interaction with other proteins.
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4.7. Vaccinia A41L
To date Oxford have solved four VACV protein structures,
one of which, A41L, shares sequence similarity to several
chemokine-binding proteins and is thought to play a role in
reducing inflammatory responses to viral infection. Mutants of
VACV deficient in A41L are readily cleared by the immune
system and the A41L protein has also been shown to reduce
the infiltration of inflammatory cells into infected areas of host
immune systems in animal models. Oxford produced and
purified A41L using the standard pipeline for expression in
E. coli, followed by a generic refolding protocol, as mentioned
above. Refolded protein was quality-assessed by MS. Crystal
screens and optimizations were performed using the HTP
protocols developed in Oxford (Walter et al., 2003; Brown et
al., 2003; Walter et al., 2005). The structure was solved by the
MAD technique at the UK beamline BM14 (Grenoble) using
SeMet-labelled A41L protein (M. Bahar, unpublished work).
A41L is a single-domain protein with a core fold that adopts a
distinct -sandwich topology. The -sandwich is defined by
two -sheets arranged parallel to each other (Fig. 3) and
connected by an array of long loops. VACVA41L is structu-
rally similar to the 35K chemokine-binding protein of the
related cowpox virus. Work is under way to identify the
chemokines to which the molecule binds, but it is clear from
the structure that the interactions are somewhat unusual since
the protein does not possess the overwhelmingly negatively
charged surface usually associated with chemokine-binding
proteins.
4.8. Epstein–Barr virus dUTPase
The EBV project in Grenoble attempted a structural
genomics approach to enzymes of this virus; however, most
aspects of the activity were not performed in HTP mode
(Tarbouriech et al., 2006). The exception to this was the use for
crystal screening of a Cartesian robot dispensing nanolitre
drops, which had a significant impact on the project (Berry et
al., 2006) and led to the determination of the structures of four
proteins. Of these, EBV dUTPase is of particular interest.
dUTPases are ubiquitous enzymes hydrolyzing dUTP in order
to maintain a low intracellular concentration of dUTP and to
minimize its incorporation in DNA. Monomeric dUTPases
only occur in herpesviruses, whereas other organisms encode
related trimeric or unrelated dimeric forms of this enzyme. For
trimeric dUTPases, the three different subunits contribute five
conserved motifs to each of the three active sites located at the
subunit interfaces. The structure of EBV dUTPase represents
the first example of a monomeric dUTPase (Tarbouriech et al.,
2005). The structure was determined in complex with the
reaction product dUMP and the substrate analogue ,-imino-
dUTP. EBV dUTPase (256 residues) consists of two domains,
each structurally similar to the subunit of the trimeric
dUTPases, which contribute motif III, and motifs I, II and IV,
respectively, to the creation of a single active site (Fig. 3). The
C-terminal motif V is largely disordered in the solved struc-
tures but is tethered near the active site by an unexpected
disulfide bridge between Cys4 and Cys246. The enzyme is a
rare example of an evolution from a multimeric to a mono-
meric protein. Presumably, a single gene-duplication event led
to a molecule which maintained an active site extremely
similar in structure to those of the trimeric enzymes. It is to be
hoped that such subtle differences between the active sites of
the viral and the human enzymes can be exploited in the
design of specific inhibitors.
5. Concluding remarks
The SPINE Project has contributed to a shift in the way
structural biology is now being carried out in Europe through
the democratization of the use of new technologies and the
development of novel strategies at various steps of the
structure-determination pipeline. Since SPINE is driven by
the notion of selecting ‘high-value human health targets’, it
was natural that a number of human pathogens were targeted
for analysis, from bacteria and viruses that cause ‘established’
human diseases to newly emerging threats to human health
(SARS-CoV). Overall, SPINE has solved a substantial
number of structures from these targets (over 220, including
65 complexes), some of which are being evaluated as possible
new drug targets. However, we have found no generic solution
to the traditional problem of protein solubility; rather, the
problem has been significantly ameliorated by the sheer
numbers of potential constructs that can be screened through
the establishment and development of parallel cloning and
expression technologies both in bacterial and eukaryotic
expression systems. For the future it seems that more
comprehensive library-based approaches (sometimes termed
‘directed evolution’) may have a substantial impact in
providing a much more extensive screening for soluble
constructs and one such approach, the ESPRIT method (see
Alzari et al., 2006), is being applied to several viral targets of
high value, including a SARS-CoV protein, in part as a
collaboration between Oxford and Grenoble (C. Meier,
unpublished results). There is considerable scope for further
developments.
The analysis of a set of relatively straightforward bacterial
targets was key to the benchmarking of the techniques used
and developed in SPINE, especially for protein over-
expression and purification. The York/Oxford collaboration
on B. anthracis (Au et al., 2006) identified a number of
problems in the first generation of protocols, such as the
insolubility of certain Gateway constructs. The failure to
overexpress significant amounts of soluble protein could easily
have been put down to the challenging nature of human and
human viral targets if only these problems had been used to
test pipelines. The work on bacterial targets pinpointed the
problems and provided a convenient and reliable benchmark
for their resolution. In addition, the B. anthracis project has
led to the determination of 45 structures to date, which
demonstrates the high success rate which can be achieved with
the refined pipelines (up to 30%). In addition, the bacterial
projects facilitated the ready sharing of knowledge, technol-
ogies and technique, which has contributed greatly to the
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establishment of European HTP activities, and the dissemi-
nation of technologies to the wider community.
The production of soluble proteins for certain eukaryotic
viral targets was poor in E. coli and in terms of amenability to
overexpression in soluble form at suitable concentrations for
NMR or protein crystallography these proteins behave more
like human proteins. For these targets, eukaryotic expression
systems such as baculovirus and mammalian cells provide
powerful alternative vehicles for the production of soluble
protein. It is interesting to note that the pattern of soluble
protein expression across different viruses can vary markedly.
Whereas herpes viral structural proteins were in general
intractable in E. coli, there was a higher success rate with
proteins from viruses such as VACV (from a small target set of
ten, three crystal structures have been solved).
This work was funded by the European Commission as
SPINE, Structural Proteomics In Europe, contract No. QLG2-
CT-2002-00988 under the Integrated Programme ‘Quality of
Life and Management of Living Resources’.
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